Article

Experimental Drug Likely Saved Ebola Patients

On July 30, the Defense Threat Reduction Agency, an arm of the military responsible for any chemical, biological, radiological, nuclear and high-yield explosive threats, allotted additional funding to MAPP Biopharmaceutical due to "promising results."

On Thursday, Dr. Kent Brantly thought he was going to die. It was the ninth day since the American missionary worker came down sick with Ebola in Liberia. His condition worsening by the minute, Brantly called his wife to say goodbye. Thankfully, the call was premature.

Brantly is back on his feet -- literally -- after receiving a last-ditch, highly experimental drug. Another American missionary with Ebola got the same.

Brantly's and Nancy Writebol's conditions significantly improved after receiving the medication, sources say. Brantly was able to walk into Emory University Hospital in Atlanta after being evacuated to the United States last week, and Writebol is expected to arrive in Atlanta on Tuesday.

Read the full story here: http://cnn.it/1nllZJQ

Source: CNN

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Carla Nester, MD, MSA, FASN, Stead Family Children's Hospital
Dr John Mascarenhas
Dr Xavier Leleu
Dr Xavier Leleu
Francesco Sparano, MSc
Dr Sundar Jagannath
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo